Affiliation:
1. University of Minnesota
2. Iowa State University
3. Ceva Sante Animale
4. Attoquant Diagnostics
Abstract
Abstract
Objective –
To characterize the dose-exposure-response effect of spironolactone on biomarkers of the classical and alternative arms of the renin-angiotensin-aldosterone system (RAAS) in healthy dogs.
Animals –
Ten healthy purpose-bred Beagle dogs.
Procedures –
Study dogs were randomly allocated to 2 spironolactone dosing groups (2 mg/kg PO q24hr, 4 mg/kg PO q24hr). The dogs received 7-day courses of spironolactone followed by a 14-day washout period in a crossover (AB/BA) design. Angiotensin peptides and aldosterone were measured in serum using equilibrium analysis, and plasma canrenone and 7-α-thiomethyl spironolactone (TMS) were quantified via liquid chromatography-mass spectrometry/mass spectroscopy (LC-MS/MS). Study results were compared before and after dosing and between groups.
Results –
Following spironolactone treatment, dogs had a significant increase in serum aldosterone concentration (P = 0.07), with no statistical differences between dosing groups. Significant increases in angiotensin II (P = 0.09), angiotensin I (P = 0.08), angiotensin 1–5 (P = 0.08), and a surrogate marker for plasma renin activity (P = 0.06) were detected compared to baseline following spironolactone treatment during the second treatment period only. Overall, changes from baseline did not significantly differ between spironolactone dosages. RAAS analytes were weakly correlated (R < 0.4) with spironolactone dosage and plasma canrenone or plasma TMS. There were no adverse clinical or biochemical effects seen at any spironolactone dosage during treatment.
Conclusions –
Treatment with spironolactone increased serum aldosterone concentration in healthy dogs and impacted other biomarkers of the classical and alternative arms of the RAAS. There was no difference in effect on the RAAS between 2 and 4 mg/kg/day dosing. Dosage of 4 mg/kg/day was safe and well-tolerated in healthy dogs.
Publisher
Research Square Platform LLC
Reference36 articles.
1. The effect of spironolactone on morbidity and mortality in patients with severe heart failure;Pitt B;New Engl J Med,2008
2. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease;Bernay F;J Vet Intern Med,2010
3. Clinical efficacy of benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The Benazepril Spironolactone Study (BESST);Coffman M;J Vet Intern Med,2021
4. The incidence and implications of aldosterone breakthrough;Bomback AS;Nat Clin Pract Nephrol,2007
5. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac;Macfadyen RJ;failure? Heart,1999